Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · IEX Real-Time Price · USD
3.420
0.00 (0.00%)
At close: Apr 26, 2024, 4:00 PM
3.510
+0.090 (2.63%)
After-hours: Apr 26, 2024, 7:17 PM EDT
Sutro Biopharma Revenue
In the year 2023, Sutro Biopharma had annual revenue of $153.73M with 126.84% growth. Revenue in the quarter ending December 31, 2023 was $113.72M with 1,217.44% year-over-year growth.
Revenue (ttm)
$153.73M
Revenue Growth
+126.84%
P/S Ratio
1.71
Revenue / Employee
$509,043
Employees
302
Market Cap
263.07M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 153.73M | 85.96M | 126.84% |
| Dec 31, 2022 | 67.77M | 5.89M | 9.52% |
| Dec 31, 2021 | 61.88M | 19.16M | 44.84% |
| Dec 31, 2020 | 42.72M | -14.00K | -0.03% |
| Dec 31, 2019 | 42.74M | 4.32M | 11.24% |
| Dec 31, 2018 | 38.42M | -13.32M | -25.75% |
| Dec 31, 2017 | 51.74M | -7.99M | -13.38% |
| Dec 31, 2016 | 59.73M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bioventus | 512.35M |
| Vanda Pharmaceuticals | 192.64M |
| Enanta Pharmaceuticals | 73.62M |
| Werewolf Therapeutics | 19.94M |
| Inovio Pharmaceuticals | 832.01K |
STRO News
- 25 days ago - Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering - GlobeNewsWire
- 25 days ago - Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors - GlobeNewsWire
- 4 weeks ago - Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones - GlobeNewsWire
- 2 months ago - Sutro Biopharma to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC - GlobeNewsWire
- 4 months ago - Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024 - GlobeNewsWire
- 4 months ago - Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023 - GlobeNewsWire
- 5 months ago - Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit - GlobeNewsWire